Download PDF
Semin intervent Radiol 2019; 36(04): 326-333
DOI: 10.1055/s-0039-1700567
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Microwave Ablation in Primary Lung Malignancies

Amgad M. Moussa
1   Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
Etay Ziv
1   Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
Stephen B. Solomon
1   Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
Juan C. Camacho
1   Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
31 October 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide. Eighty-five percent of cases correspond to non-small cell lung cancer (NSCLC) and pivotal nonsurgical options for early-stage disease include percutaneous ablation and stereotactic body radiation therapy (SBRT). Microwave Ablation (MWA) is a locoregional treatment option that has many advantages over radiofrequency ablation and has been able to overcome the limitations of this technique in the treatment of early-stage NSCLC. In this review article, we highlight the current evidence supporting the use of MWA in patients with early-stage NSCLC and discuss the technical considerations of the procedure, including optimal patient selection and planning strategies, as well as the potential complications and reported outcomes. Finally, we mention future trends involving ablation in NSCLC, including its role in combination with SBRT in central tumors, management of post-SBRT local recurrence, and its potential as an adjuvant treatment option for patients with resistance to systemic therapy or in combination with checkpoint inhibitors.

Keywords

primary lung tumors - microwave ablation - NSCLC
 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68 (01) 7-30
    CrossrefPubMedGoogle Scholar
  • 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 3 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83 (05) 584-594
    CrossrefPubMedGoogle Scholar
  • 4 Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res 2016; 5 (01) 26-38
    PubMedGoogle Scholar
  • 5 Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013; 82 (02) 179-189
    CrossrefPubMedGoogle Scholar
  • 6 Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res (Phila) 2016; 9 (07) 518-527
    CrossrefPubMedGoogle Scholar
  • 7 National Comprehensive Cancer Network Guidelines. Non-Small Cell Lung Cancer. Version 3; February 21, 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed October 4, 2019
    PubMedGoogle Scholar
  • 8 Ginsberg RJ, Rubinstein LV. ; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995; 60 (03) 615-622 , discussion 622–623
    CrossrefPubMedGoogle Scholar
  • 9 Al Torki N. Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT00499330 . Accessed October 4, 2019
    PubMedGoogle Scholar
  • 10 Timmerman R, Paulus R, Galvin J. , et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11) 1070-1076
    CrossrefPubMedGoogle Scholar
  • 11 Dupuy DE, Fernando HC, Hillman S. , et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer 2015; 121 (19) 3491-3498
    CrossrefPubMedGoogle Scholar
  • 12 Bi N, Shedden K, Zheng X, Kong FS. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable Stage I non-small cell lung cancer: a systemic review and pooled analysis. Int J Radiat Oncol Biol Phys 2016; 95 (05) 1378-1390
    CrossrefPubMedGoogle Scholar
  • 13 Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival rates after thermal ablation versus stereotactic radiation therapy for Stage 1 non-small cell lung cancer: a national cancer database study. Radiology 2018; 289 (03) 862-870
    CrossrefPubMedGoogle Scholar
  • 14 Pereira PL, Masala S. ; Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol 2012; 35 (02) 247-254
    CrossrefPubMedGoogle Scholar
  • 15 Frakulli R, Salvi F, Balestrini D. , et al. Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2017; 6 (Suppl. 01) S1-S7
    PubMedGoogle Scholar
  • 16 Clasen S, Krober SM, Kosan B. , et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer 2008; 113 (11) 3121-3129
    CrossrefPubMedGoogle Scholar
  • 17 Yasui K, Kanazawa S, Sano Y. , et al. Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience. Radiology 2004; 231 (03) 850-857
    CrossrefPubMedGoogle Scholar
  • 18 Palma DA, Nguyen TK, Louie AV. , et al. Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol 2019; 5 (05) 681-688
    CrossrefPubMedGoogle Scholar
  • 19 Crabtree T, Puri V, Timmerman R. , et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 2013; 145 (03) 692-699
    CrossrefPubMedGoogle Scholar
  • 20 de Baere T, Tselikas L, Catena V, Buy X, Deschamps F, Palussière J. Percutaneous thermal ablation of primary lung cancer. Diagn Interv Imaging 2016; 97 (10) 1019-1024
    CrossrefPubMedGoogle Scholar
  • 21 Rose SC, Thistlethwaite PA, Sewell PE, Vance RB. Lung cancer and radiofrequency ablation. J Vasc Interv Radiol 2006; 17 (06) 927-951 , quiz 951
    CrossrefPubMedGoogle Scholar
  • 22 Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S192-S203
    CrossrefPubMedGoogle Scholar
  • 23 Brace CL, Hinshaw JL, Laeseke PF, Sampson LA, Lee Jr FT. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology 2009; 251 (03) 705-711
    CrossrefPubMedGoogle Scholar
  • 24 Healey TT, March BT, Baird G, Dupuy DE. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J Vasc Interv Radiol 2017; 28 (02) 206-211
    CrossrefPubMedGoogle Scholar
  • 25 Postmus PE, Kerr KM, Oudkerk M. , et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv1-iv21
    CrossrefPubMedGoogle Scholar
  • 26 Shi F, Li G, Zhou Z. , et al. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. Oncotarget 2017; 8 (65) 109791-109798
    CrossrefPubMedGoogle Scholar
  • 27 Yuan Z, Wang Y, Zhang J, Zheng J, Li W. A Meta-analysis of clinical outcomes after radiofrequency ablation and microwave ablation for lung cancer and pulmonary metastases. J Am Coll Radiol 2019; 16 (03) 302-314
    CrossrefPubMedGoogle Scholar
  • 28 Abtin F, De Baere T, Dupuy DE. , et al. Updates on current role and practice of lung ablation. J Thorac Imaging 2019; 34 (04) 266-277
    CrossrefPubMedGoogle Scholar
  • 29 Moreland A, Novogrodsky E, Brody L. , et al. Pneumothorax with prolonged chest tube requirement after CT-guided percutaneous lung biopsy: incidence and risk factors. Eur Radiol 2016; 26 (10) 3483-3491
    CrossrefPubMedGoogle Scholar
  • 30 Lee KS, Takaki H, Yarmohammadi H. , et al. Pleural puncture that excludes the ablation zone decreases the risk of pneumothorax after percutaneous microwave ablation in porcine lung. J Vasc Interv Radiol 2015; 26 (07) 1052-1058
    CrossrefPubMedGoogle Scholar
  • 31 Hiraki T, Gobara H, Fujiwara H. , et al. Lung cancer ablation: complications. Semin Intervent Radiol 2013; 30 (02) 169-175
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Jia H, Tian J, Liu B, Meng H, Pan F, Li C. Efficacy and safety of artificial pneumothorax with position adjustment for CT-guided percutaneous transthoracic microwave ablation of small subpleural lung tumors. Thorac Cancer 2019; 10 (08) 1710-1716
    CrossrefPubMedGoogle Scholar
  • 33 de Baere T, Farouil G, Deschamps F. Lung cancer ablation: what is the evidence?. Semin Intervent Radiol 2013; 30 (02) 151-156
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Smith SL, Jennings PE. Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances. Br J Radiol 2015; 88 (1046): 20140598
    CrossrefPubMedGoogle Scholar
  • 35 Kashima M, Yamakado K, Takaki H. , et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences. AJR Am J Roentgenol 2011; 197 (04) W576-W580
    CrossrefPubMedGoogle Scholar
  • 36 Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology 2008; 247 (03) 871-879
    CrossrefPubMedGoogle Scholar
  • 37 Chheang S, Abtin F, Guteirrez A, Genshaft S, Suh R. Imaging features following thermal ablation of lung malignancies. Semin Intervent Radiol 2013; 30 (02) 157-168
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Abtin FG, Eradat J, Gutierrez AJ, Lee C, Fishbein MC, Suh RD. Radiofrequency ablation of lung tumors: imaging features of the postablation zone. Radiographics 2012; 32 (04) 947-969
    CrossrefPubMedGoogle Scholar
  • 39 Zheng A, Ye X, Yang X, Huang G, Gai Y. Local efficacy and survival after microwave ablation of lung tumors: a retrospective study in 183 patients. J Vasc Interv Radiol 2016; 27 (12) 1806-1814
    CrossrefPubMedGoogle Scholar
  • 40 Gao S, Stein S, Petre EN. , et al. Micropapillary and/or solid histologic subtype based on pre-treatment biopsy predicts local recurrence after thermal ablation of lung adenocarcinoma. Cardiovasc Intervent Radiol 2018; 41 (02) 253-259
    CrossrefPubMedGoogle Scholar
  • 41 Luo J, Wang R, Han B. , et al. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma. Oncotarget 2017; 8 (04) 7050-7058
    CrossrefPubMedGoogle Scholar
  • 42 Tsakok MT, Little MW, Hynes G. , et al. Local control, safety, and survival following image-guided percutaneous microwave thermal ablation in primary lung malignancy. Clin Radiol 2019; 74 (01) 80.e19-80.e26
    CrossrefPubMedGoogle Scholar
  • 43 Erinjeri JP, Clark TWI. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S187-S191
    CrossrefPubMedGoogle Scholar
  • 44 Moore W, Talati R, Bhattacharji P, Bilfinger T. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol 2015; 26 (03) 312-319
    CrossrefPubMedGoogle Scholar
  • 45 Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 2010; 211 (01) 68-72
    CrossrefPubMedGoogle Scholar
  • 46 Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010; 255 (02) 426-433
    CrossrefPubMedGoogle Scholar
  • 47 Ricke J, Jürgens JHW, Deschamps F. , et al. Irreversible electroporation (IRE) fails to demonstrate efficacy in a prospective multicenter phase II trial on lung malignancies: the ALICE trial. Cardiovasc Intervent Radiol 2015; 38 (02) 401-408
    CrossrefPubMedGoogle Scholar
  • 48 Tian S, Higgins KA, Curran WJ, Cassidy RJ. Stereotactic body radiation therapy vs. surgery in early-stage non-small cell lung cancer: lessons learned, current recommendations, future directions. J Thorac Dis 2018; 10 (03) 1201-1204
    CrossrefPubMedGoogle Scholar
  • 49 Yao W, Lu M, Fan W. , et al. Comparison between microwave ablation and lobectomy for stage I non-small cell lung cancer: a propensity score analysis. Int J Hyperthermia 2018; 34 (08) 1329-1336
    CrossrefPubMedGoogle Scholar
  • 50 Sandler KA, Abtin F, Suh R. , et al. A prospective phase 2 study evaluating safety and efficacy of combining stereotactic body radiation therapy with heat-based ablation for centrally located lung tumors. Int J Radiat Oncol Biol Phys 2018; 101 (03) 564-573
    CrossrefPubMedGoogle Scholar
  • 51 Leung VA, DiPetrillo TA, Dupuy DE. Image-guided tumor ablation for the treatment of recurrent non-small cell lung cancer within the radiation field. Eur J Radiol 2011; 80 (03) e491-e499
    CrossrefPubMedGoogle Scholar
  • 52 Brooks ED, Sun B, Feng L. , et al. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer. JAMA Netw Open 2018; 1 (04) e181390
    CrossrefPubMedGoogle Scholar
  • 53 Ni Y, Liu B, Ye X. , et al. Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease. Cardiovasc Intervent Radiol 2019; 42 (05) 693-699
    CrossrefPubMedGoogle Scholar
  • 54 Zheng A, Wang X, Yang X. , et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg 2014; 98 (01) 243-248
    CrossrefPubMedGoogle Scholar